UCB SA (UCB):企業の財務・戦略的SWOT分析

【英語タイトル】UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(DATA904C0584)・商品コード:DATA904C0584
・発行会社(調査会社):GlobalData
・発行日:2018年7月
・ページ数:56
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

UCB SA (UCB) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It principally focuses on developing products for the treatment of central nervous system (CNS) and immunology related conditions. The company’s key medicines include Cimzia for ankylosing spondylitis, axial spondylarthritis, Crohn’s disease, psoriatic arthritis and rheumatoid arthritis; Neupro for Parkinson’s disease and restless legs syndrome; and Vimpat, Keppra and Briviact for epilepsy. UCB is also developing new therapies for neurological and immunological diseases. The company operates subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Belgium.

UCB SA Key Recent Developments

Jun 28,2018: New UCB Research Showcases Value of CIMZIA (certolizumab pegol) in Psoriasis and Highlights Unique Experiences and Real World Evidence for Key Patient Populations
Jun 19,2018: Succeeding together UCB joins patients and experts to improve the lives of people with epilepsy[TOPC : Pharma - UCB SA]
Jun 15,2018: New Study Presented at the Annual European Congress of Rheumatology (EULAR 2018) Reveals Insights About Women with Chronic Rheumatic Diseases During Their Pregnancy Journey
Jun 01,2018: UCB proud to collect Wallonia Export Award
May 22,2018: UCB joins with ILAE and IBE to encourage World Health Assembly members to continue recognition of epilepsy as global health priority

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
UCB SA – Key Facts 6
UCB SA – Key Employees 7
UCB SA – Key Employee Biographies 8
UCB SA – Major Products and Services 9
UCB SA – History 10
UCB SA – Company Statement 17
UCB SA – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Joint Venture 22
Section 2 – Company Analysis 23
Company Overview 23
UCB SA – Business Description 24
UCB SA – Corporate Strategy 25
UCB SA – SWOT Analysis 26
SWOT Analysis – Overview 26
UCB SA – Strengths 26
UCB SA – Weaknesses 27
UCB SA – Opportunities 28
UCB SA – Threats 29
UCB SA – Key Competitors 30
Section 3 – Company Financial Ratios 31
Financial Ratios – Capital Market Ratios 31
Financial Ratios – Annual Ratios 32
Performance Chart 35
Financial Performance 35
Financial Ratios – Interim Ratios 36
Financial Ratios – Ratio Charts 37
Section 4 – Company’s Lifesciences Financial Deals and Alliances 38
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 38
UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 39
UCB SA, Recent Deals Summary 40
Section 5 – Company’s Recent Developments 41
Jun 19, 2018: Succeeding together UCB joins patients and experts to improve the lives of people with epilepsy[TOPC : Pharma - UCB SA] 41
Jun 15, 2018: New Study Presented at the Annual European Congress of Rheumatology (EULAR 2018) Reveals Insights About Women with Chronic Rheumatic Diseases During Their Pregnancy Journey 42
Jun 01, 2018: UCB proud to collect Wallonia Export Award 43
May 22, 2018: UCB joins with ILAE and IBE to encourage World Health Assembly members to continue recognition of epilepsy as global health priority 44
May 07, 2018: Partnership with Science 37: helping UCB to improve patient experience 45
May 03, 2018: Science 37 Partners with UCB to Fundamentally Change the Clinical Trial Ecosystem, Focusing on More Patient-Friendly, Technology-Enabled Trials at Home 46
Apr 23, 2018: Sharing research & supporting development of future neurology leaders at AAN 2018 47
Mar 22, 2018: CIMZIA Label Update Marks Major Advance For Women Of Childbearing Age With Chronic Inflammatory Disease In U.S. 49
Mar 21, 2018: GoBoldy: R&D Is An Investment In New Era Of Medicine 50
Mar 06, 2018: New online tool helps patients and physicians find our clinical studies 51
Section 6 – Appendix 52
Methodology 52
Ratio Definitions 52
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
UCB SA, Key Facts 6
UCB SA, Key Employees 7
UCB SA, Key Employee Biographies 8
UCB SA, Major Products and Services 9
UCB SA, History 10
UCB SA, Subsidiaries 19
UCB SA, Joint Venture 22
UCB SA, Key Competitors 30
UCB SA, Ratios based on current share price 31
UCB SA, Annual Ratios 32
UCB SA, Annual Ratios (Cont...1) 33
UCB SA, Annual Ratios (Cont...2) 34
UCB SA, Interim Ratios 36
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 38
UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 39
UCB SA, Recent Deals Summary 40
Currency Codes 52
Capital Market Ratios 52
Equity Ratios 53
Profitability Ratios 53
Cost Ratios 54
Liquidity Ratios 54
Leverage Ratios 55
Efficiency Ratios 55

List of Figures
UCB SA, Performance Chart (2013 - 2017) 35
UCB SA, Ratio Charts 37
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 38
UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 39

★調査レポート[UCB SA (UCB):企業の財務・戦略的SWOT分析] (コード:DATA904C0584)販売に関する免責事項を必ずご確認ください。
★調査レポート[UCB SA (UCB):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆